Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05250817 · ClinicalTrials.gov registry record

A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by Bristol-Myers Squibb.

Completed
Registry status
501
Enrollment target
1
Study location

NCT05250817: Completed study of Carcinoma, Non-Small Cell Lung, sponsored by Bristol-Myers Squibb.

NCT05250817 is a study of Carcinoma, Non-Small Cell Lung that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 501 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (57% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05250817, a study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
501 participants
Enrollment target
1
Study location

Study Summary

The purpose of this observational study is to determine participants' preferences for outcomes associated with first-line treatment of advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) using a discrete-choice experiment (DCE).

Conditions Studied

Carcinoma, Non-Small Cell Lung

Study Locations (1)

North Carolina

  • RTI Health Solutions - Research Triangle Park

Trial Details

FieldValue
Enrollment Target 501 participants
Start Date 2021-12-09
Est. Completion 2023-01-04
Bristol-Myers Squibb

1,025 total trials

What the finished NCT05250817 record still lists

NCT05250817 is an observational study that tracks outcomes without assigning an intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (57% higher).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 0 interventions.

NCT05250817 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05250817 about?

NCT05250817 is a clinical study titled "A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer". The purpose of this observational study is to determine participants' preferences for outcomes associated with first-line treatment of advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) using a discrete-choice experiment (DCE).

What is the current status of trial NCT05250817?

This trial is currently completed. The enrollment target is 501 participants. The study started on 2021-12-09. Estimated completion is 2023-01-04.

What conditions does trial NCT05250817 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

Who is sponsoring clinical trial NCT05250817?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05250817 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05250817's enrollment target sits among peer trials

501 29th of 130 higher than 102 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04442022 · 501 participants · Phase 2

    A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • NCT06934525 · 501 participants · NA

    Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings

  • NCT05646381 · 502 participants · Phase 2

    A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

  • NCT05897632 · 502 participants · NA

    CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05250817, the US trial registry maintained by the National Library of Medicine. NCT05250817 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.